

Arterez Inc.
10720 Jacobs Ct.
White Lake, MI 48386

Dr. Joe Tunac, President & Chairman
248.763.1426
drjoe@arterez.com

Mike Brennan, CEO
248.931.9091
mike@arterez.com

Brett Homovec, CFO
248.202.2275
brett@arterez.com

Novel Technology Platform:

Anti-Thrombotic Oral Therapies

*Embotricin™ triple compound oral therapy –
Targets endothelial glycocalyx repair and
maintenance, inflammation and oxidation*

Therapeutic Aide & Diagnostic Tools

*GlycoCardia™ therapeutic aide –
Multiplex kit designed to monitor drug efficacy*
*Glycalyx Detritus Fingerprint™ technology –
Disease identification & characterization*

Intellectual Properties:

- a. (Issued) Biomarkers of Vascular Disease
- b. (Issued) Methods and Compositions for Reversing Disruption of the Glycocalyx, Inflammation and Oxidative Damage
- c. (Pending) Drug Treatment and Biomarker Panel Targeted to Diseases Due to Multifactorial Ontology of Glycocalyx Disruption
- d. (Draft) Animal Model for CVD and Inflammation
- e. PCT and additional IP submissions are in progress

Clinical Targets:

*Embotricin™ IND/FDA indications:
Pulmonary Hypertension (IND target)
Dialysis Fistula (IND optional)*

*Embotricin™ Proof of Principle/non-US:
Heart Failure
Cardiovascular Artery Disease*

*GlycoCardia™ therapeutic aide
Multiplex kit/algorithm/s validation*

Pre-clinical Providers:

DSK Biopharma – *compound manufacturing*
Cambrex – *GLP/GMP, analysis and formulation*
Wayne State University – *ELISA studies*
Henry Ford Health System – *translational studies*
Camargo Research – *CRO selection and oversight*
Camargo or Medpace Regulatory – *IND, toxicology*
Various CROs – *pre-clinical studies*
Utah State University – *corona virus pollutant study*
Clinical Network Svcs. – *GAP analysis/AUS dev plan*

Clinical Providers:

Transhit-Bio – *clinical bio-samples sourcing*
Arbor Assays – *ELISA serum & plasma studies*
Meehage M. Perera, Ph.D – *Biomarker algorithm dev*
TBD – *clinical investigator (US and AUS)*
Dr. Bonnie Weiner – *clinical strategy & investigation*

Legal and Advisory:

Weaver Austin Villeneuve & Sampson LLP
Intellectual Properties
Bodman PLC
Corporate filings, offering documentation
Varnum LLP
Trademarks, Publishing
Garrett & Bachand PC
General Counsel
Croskey Lanni
Corporate Accounting
ABA Consulting
Corporate Advisory (AUS)

Executive Overview:

Cardiovascular Disease (CVD) is the world's leading chronic killer impacting more than one-third of the world's population. US direct and indirect healthcare costs due to CVD is expected to grow to an estimated \$1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost.

Arterez is a Michigan biosciences group that beginning in 2012 discovered chronic vascular disease share common, multi-factorial 'root' cause etiology including damage to the endothelial glycocalyx, inflammation and oxidation thus require a synergistic therapeutic approach to enable curative and preventive outcomes.

The company developed and tested 9 NCE's in 30+ combinations and has since developed Embotricin™, a fixed dose oral drug targeting the primary root causes of CVD as well as a biomarker panel for treatment monitoring, GlycoCardia™. While developing GlycoCardia™, we discovered patterns or fingerprints of vascular disease we also intend to develop known as the Glycalyx Detritus Fingerprint™ system for vascular disease identification and classification. Embotricin™ proved to prevent formation of emboli (clots) involving plaque regression and restoration of the glycocalyx, proved non-toxic up to 1000mg/kg in mice (300/1), has an effective dose of 3mg/kg and also proved efficacious vs. sars-cov1 (published).

Funding of \$10 million dollars is required to complete pre-IND, GLP refinement and scale-up, analysis and formulation, toxicology, FDA IND and cGMP manufacturing as well as algorithm and multiplex kit development.

First in-human studies are expected to begin Q1 2023. GAP, risk analysis, regulatory and development, Gantt and capital requirements have been developed to meet our clinical objectives.

Company/Technology Summary:

- a. Dr. Tunac invested and raised \$3.5 million dollars prior to the company formation in 2018. Since, the company has secured \$1.56 million. An estimated \$22.5M will be required to complete first in-human trials and position the company for targeted acquisition of Arterez' 1st indication, enabling a public offering designed to provide shareholder liquidity and fund future platform research and development.
- b. Arterez enjoys independent IP valuation assessments of \$105 million for our therapy vs three targeted indications and \$471 million for our patent portfolio.
- c. Embotricin™ proved to prevent formation of emboli (clots) involving plaque regression and/or restoration of the endothelial glycocalyx and has demonstrated no toxicity up to 300x the effective dose in a 30-day tox study.
- d. Dr. Tunac developed and synthesized 9 active compounds leading to the abbreviated factorial 3-drug combo design Embotricin™. Testing showed activity vs. other chronic diseases such as diabetes type II and arthritis. These can also be developed following successful first in human trial/s.
- e. Patent portfolio includes; a. (issued) methods and compositions for reversing disruption of the glycocalyx, inflammation and oxidative damage, b. (issued) biomarkers of vascular disease, c. (pending) drug treatment and biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption, d. (draft) Thromboembolic animal model for CVD and inflammation. PCT is filed and trademarks are approved with more in process.
- f. First in-human studies for Embotricin™ and therapeutic aide GlycoCardia™ are expected to begin 2023 in the US and out of country for proof of principle studies concurrently.
- g. Access to our proprietary data-room can be provided with an executed NDA.

In conclusion

We believe our discoveries may be a profound scientific breakthrough that could lead to a new paradigm for the identification, characterization and treatment of CVD and other vascular diseases leading to predictive, curative and preventive outcomes rather than palliative treatments currently available. Its time we solve this terrible problem for humanity. Please contact us to learn more.